Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Prostate Cancer Active Surveillance Metformin Trial

This study has been withdrawn prior to enrollment.
(The reason for this decision is that this study is being merged with a larger multi-centre study using the same agent in the same population.)
Sponsor:
Information provided by (Responsible Party):
University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT01733836
First received: November 20, 2012
Last updated: May 23, 2013
Last verified: May 2013

November 20, 2012
May 23, 2013
January 2013
October 2014   (final data collection date for primary outcome measure)
  • Primary Clinical Outcome - Inhibition of Prostate Cancer [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]
    To assess the role of metformin on the inhibition of low-risk localized prostate cancer progression in men undergoing active surveillance for prostate cancer.
  • Primary Scientific Endpoint - ki67 index [ Time Frame: 18 months ] [ Designated as safety issue: No ]
    To assess the effect of metformin on the cell cycle proliferation indices (ki67 index).
Same as current
Complete list of historical versions of study NCT01733836 on ClinicalTrials.gov Archive Site
  • Secondary Endpoint - Cell Cycle Proliferation (CCP) Score [ Time Frame: 18 months ] [ Designated as safety issue: No ]
    To assess the effect of metformin on the cell cycle proliferation indices (CCP score)
  • Secondary Endpoint - Mechanism of Action [ Time Frame: 18 months ] [ Designated as safety issue: No ]
    To assess the effect of metformin on systemic and local signalling axes and morphometric measurements relevant to its mechanism of action.
  • Secondary endpoint - Quality of Life [ Time Frame: 18 months ] [ Designated as safety issue: No ]
    To assess the impact of metformin on Quality of Life (QoL) indices.
  • Secondary Endpoint - Prognostic Panel [ Time Frame: 18 months ] [ Designated as safety issue: No ]
    To determine the utility of a prognostic panel of 31 cell cycle progression genes recently validated in prostate cancer.
Same as current
Not Provided
Not Provided
 
Prostate Cancer Active Surveillance Metformin Trial
A Randomized Double Blind Placebo Controlled Single Institution Phase 2 Study of Metformin in Patients Undergoing Active Surveillance for Prostate Cancer.

To determine whether the use of metformin in patients with low-risk prostate cancer can delay progression to clinically significant prostate cancer.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Prostate Cancer
  • Drug: Metformin
  • Drug: placebo
  • Experimental: Metformin
    850mg BID
    Intervention: Drug: Metformin
  • Placebo Comparator: Placebo
    Intervention: Drug: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
October 2014
October 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Willing and able to provide informed consent
  • Men >= 18 years of age, and less than 80
  • Men with biopsy proven, low-risk, localized prostate cancer (as defined below)
  • Men choosing expectant management as primary treatment for prostate cancer
  • Diagnostic biopsy performed within 4 months of screening visit
  • Gleason score ≤ 6 in 3 cores or less with no Gleason pattern 4, less than 50% of any core involved in cancer
  • Clinical stage T1c-T2a (Initial diagnosis of T1a/T1b obtained during a TURP is not allowed)
  • Serum PSA ≤10 ng/mL
  • Life expectancy greater than 5 years
  • Normal kidney and hepatic function as defined by the following criteria:

    • Total bilirubin less than 1.5 X institutional upper limit of normal (ULN)
    • AST (SGOT)/ALT(SGPT) less than 1.5 X institutional ULN
    • Alkaline phosphatase less than 2 X institutional ULN
    • Creatinine less than 1.4 X institutional ULN
  • Able to swallow and retain oral medication
  • No exposure to metformin within 12 months of randomization
  • No known hypersensitivity or intolerance to metformin hydrochloride
  • No condition associated with increased risk of metformin hydrochloride-associated lactic acidosis (e.g., congestive heart failure defined as NYHA class III or IV function status, history of acidosis of any type, or habitual intake of ≥ 3 alcoholic beverages per day, or age greater than 80)
  • English fluency allowing for patient reported outcomes completion

Exclusion Criteria:

  • Any previous prostate cancer treatment (radiotherapy, chemotherapy, hormonal therapy, oral glucocorticoids, GnRH analogues)
  • Diabetes including type 1 diabetes. Patients with known type 2 diabetes are eligible provided they have not been on metformin during the previous 12 months and are not on any other pharmacological agents.
  • Concurrent or previous use of anabolic steroids or drugs with anti androgenic properties including 5-ARIs (dutasteride and finasteride)
  • Prostate volume greater than 80 cc. (as per TRUS biopsy report)
  • Prostatic surgery or procedure within 3 months of screening visit
  • Severe BPH symptoms (IPSS ≥25, or ≥20 if already on α-blocker therapy)
  • Other malignancies, with the exception of adequately treated nonmelanoma skin cancer, NMIBC or other solid tumors curatively treated with no evidence of disease for ≥ 5 years
  • Planned or concurrent participation in other interventional randomized trials including exercise
  • The presence of any other coexistent medical condition that in the opinion of the investigator would have the potential to significantly limit adherence to medication, or ability to absorb the medication including but not limited to psychiatric conditions, malabsorption syndromes or severe ischemic heart disease
  • Known hypersensitivity or intolerance to metformin
  • Concurrent or planned participation in randomized trials of weight loss or exercise interventions or trials targeting insulin, IGF-1 or their receptors, or PI3K inhibitors.
Male
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT01733836
MAS_001
Yes
University Health Network, Toronto
University Health Network, Toronto
Not Provided
Not Provided
University Health Network, Toronto
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP